Imagine a world in which access to life-changing therapies transforms human health. Cytiva's team of nearly 7,000 associates across 40 countries is making it happen with breakthroughs that have shaped today's biotechnology industry. As global demand for personalized and advanced biological therapies continues to increase, in 2019, Cytiva has contributed to the research or development of 90% of today's top-selling biological therapeutics. See what we do in this video.
Cytiva's focus on customer-centric innovation and collaboration make it a trusted partner in the research and development of life-saving vaccines, biologic drugs, and novel cell and gene therapies. From idea to commercial development, Cytiva's job is to supply the tools and services researchers and biopharmaceutical producers need to work better, faster and safer.
For established biopharma and CDMOs, Cytiva offers products and solutions that allow rapid development and scaling of biomanufacturing, to meet patient demand. At every stage, improved efficiencies and productivity through innovative technologies and agile processes is essential. For example, FlexFactory and KUBio – Cytiva’s off-the-shelf biomanufacturing platforms, enable a 50% faster time-to-market for customers.
Cytiva has a proven past and a new beginning. With a rich heritage tracing back over two hundred years, the company joined Danaher in 2020.